Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib - Archive ouverte HAL Access content directly
Journal Articles Clinical Genitourinary Cancer Year : 2019

Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib

(1, 2) , (1, 2) , (1, 2) , (2) , (3) , (4, 2) , (2) , (5) , (6) , (2) , (7) , (2) , (8) , (9) , (9) , (10) , (3) , (3, 2)
1
2
3
4
5
6
7
8
9
10
Stéphane Oudard
  • Function : Author
  • PersonId : 854064
Arnaud Méjean
  • Function : Author
  • PersonId : 907550

Abstract

There are no validated markers that predict response or resistance in patients with metastatic clear-cell renal cell carcinoma (mccRCC) treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors such as sunitinib and pazopanib. Recently, single nucleotide polymorphism (SNP) rs2981582 in Fibroblast Growth Factor Receptor 2 (FGFR2) was found to be associated with clinical outcome in patients with mccRCC treated with pazopanib and sunitinib. We aimed to validate these findings in patients treated with sunitinib.MATERIALS AND METHODS:Germline DNA was collected in patients with mccRCC starting first-line systemic therapy with sunitinib. SNP rs2981582 in FGFR2 C>T was genotyped. Association of the genotype with response rate, tumor shrinkage, median progression-free survival (mPFS), and median overall survival (mOS) was studied.RESULTS:We collected clinical data from 154 patients with available germline DNA. Baseline prognostic markers were well-balanced between both subgroups. Patients with the TT genotype had a poorer outcome compared with patients with the CT/CC genotype. The median shrinkage of selected tumor target lesions during treatment with sunitinib was -16% versus -31% (P = .002), mPFS was 8 versus 15 months (P = .0007), and mOS was 22 versus 33 months (P = .04), respectively. On multivariate analysis, rs2981582 remained an independent predictor of PFS (hazard ratio, 2.858; 95% confidence interval, 1.659-4.923; P < .0001) and OS (hazard ratio, 1.795; 95% confidence interval, 1.003-3.212; P = .049).CONCLUSION:Polymorphism rs2981582 in FGFR2 is correlated to PFS and OS in patients with mccRCC treated with sunitinib. Prospective validation of the impact of this SNP is warranted.
Fichier principal
Vignette du fichier
S155876731830510X.pdf (521.25 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

inserm-02532766 , version 1 (22-10-2021)

Licence

Attribution - NonCommercial - CC BY 4.0

Identifiers

Cite

Maxime Vanmechelen, Diether Lambrechts, Thomas van Brussel, Annelies Verbiest, Gabrielle Couchy, et al.. Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib. Clinical Genitourinary Cancer, 2019, 17 (2), pp.e235-e246. ⟨10.1016/j.clgc.2018.11.002⟩. ⟨inserm-02532766⟩
65 View
16 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More